Scinai Immunotherapeutics (SCNI) Receivables (2016 - 2025)

Scinai Immunotherapeutics has disclosed Receivables across 10 years of filings, most recently posting $150000.0 for Q4 2025.

• Receivables for Q4 2025 came in at $150000.0, down 49.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $150000.0 (down 49.32% YoY), and the FY2025 annual result was $150000.0, down 49.32% from the prior year.
• Receivables came in at $150000.0 for Q4 2025 at Scinai Immunotherapeutics, down from $375000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.6 billion in Q2 2021 to a low of $5830.0 in Q1 2023.
• The 5-year median for Receivables is $375000.0 (2025), against an average of $240.4 million.
• Across the five-year window, Receivables grew 7.05% in 2021 and tumbled 99.99% in 2022, its largest moves.
• Scinai Immunotherapeutics' Receivables stood at $651000.0 in 2021, then tumbled by 68.97% to $202000.0 in 2022, then sank by 97.11% to $5830.0 in 2023, then soared by 4977.19% to $296000.0 in 2024, then tumbled by 49.32% to $150000.0 in 2025.
• The last three Receivables figures came in at $150000.0 (Q4 2025), $375000.0 (Q2 2025), and $296000.0 (Q4 2024), per Business Quant data.